Category: Gastroparesis

With only one drug having FDA approval for gastroparesis in decades, there is a significant unmet need for new therapeutic options. What is the new drug for gastroparesis, and what recent developments have occurred in its pharmacology, particularly regarding tradipitant and other emerging treatments?

Following an FDA mandate, metoclopramide carries a black box warning advising against its use for more than 12 weeks to treat conditions like gastroparesis due to the risk of serious, irreversible neurological side effects. The decision to use **metoclopramide for gastroparesis** must carefully weigh its short-term efficacy against the potential for long-term harm.

Gimoti (metoclopramide) is a prescription nasal spray used to relieve symptoms of acute and recurrent diabetic gastroparesis [1.3.8]. While not a primary side effect, the question of 'Does Gimoti cause weight gain?' arises, often linked to fluid retention [1.2.1, 1.2.6].